Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (NCT02446444)

🧪 Interventions in This Study

• Enzalutamide (DRUG)
• Conventional NSAA (DRUG)
• LHRHA (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (69 Sites)

Showing the first 25 of 69 sites.

• Dana Farber Cancer Institute — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Blacktown Hospital — Blacktown, New South Wales
• Campbelltown Hospital — Campbelltown, New South Wales
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Genesis Cancer Care Newcastle — Gateshead, New South Wales
• Gosford Hospital — Gosford, New South Wales
• St George Hospital — Kogarah, New South Wales
• Liverpool Hospital — Liverpool, New South Wales
• Orange Health Service — Orange, New South Wales
• Prince of Wales Hospital — Randwick, New South Wales
• Royal North Shore Hospital — St Leonards, New South Wales
• St Vincent's Hospital — Sydney, New South Wales
• Tamworth Rural Referral Hospital — Tamworth, New South Wales
• Sydney Adventist Hospital — Wahroonga, New South Wales
• Calvary Mater Newcastle — Waratah, New South Wales
• Westmead Hospital — Westmead, New South Wales
• Wollongong Hospital — Wollongong, New South Wales
• Genesis Cancer Care Queensland - Wesley and Chermside — Auchenflower, Queensland
• Townsville Hospital — Douglas, Queensland
• Royal Brisbane & Womens Hospital — Herston, Queensland
• Nambour General Hospital — Nambour, Queensland
• Radiation Oncology Services Mater Centre — South Brisbane, Queensland
• ICON - Gold Coast (formerly ROC Gold Coast) — Southport, Queensland
• ICON - Toowoomba (formerly ROC Toowoomba) — Toowoomba, Queensland

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostatic Neoplasms

• A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
• PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS — Homewood, Alabama
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
• Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,
• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer — Birmingham, Alabama

Explore by condition: All Prostatic Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.